NEW YORK (GenomeWeb News) – Biocartis today announced it is developing a workflow for extracting, amplifying, and detecting tumor DNA on its diagnostic platforms in collaboration with the Wellcome Trust Sanger Institute and Philips Research.

The test, the Swiss molecular diagnostics firm said, could lead to better clinical care and improved quality of life for patients by enabling drugs to be targeted specifically to those patients who demonstrate meaningful response to the drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.